Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers.
Julia RotowJyoti D PatelMatthew P HanleyHelena Alexandra YuMark M AwadJonathan Wade GoldmanHovav NechushtanMatthias SchefflerAllen Chung-Cheng HuangSenthil RajappaGuilherme HaradaSarah CliffordAlison D SantucciLaura SilvaRebecca TupperGeoffrey R OxnardJennifer KheraniAlexander E DrilonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
For patients with EGFR-mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib was feasible, safe, and offered clinical benefit, supporting the prospective evaluation of this combination.